Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409612 | 1.00 | NPC1 (0.59) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL13026244 | 0.92 | NPC1 (0.53) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL22295267 | 0.82 | NPC1 (0.52) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL4406274 | 0.81 | KDM4E (0.46) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL3259839 | 0.80 | ALDH1A1 (0.52) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL16264234 | 0.80 | PLAU (0.38) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL16261009 | 0.79 | ALOX15 (0.60) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL29033253 | 0.77 | NPC1 (0.65) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL4401942 | 0.76 | KMT2A (0.38) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29986357 | 0.76 | NPC1 (0.67) | NPC1POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4033223-B1 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | WATERS TECHNOLOGIES CORP (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12158472-B2 | Methods for the rapid preparation of labeled glycosylamines and for the analysis of glycosylated biomolecules producing the same | WATERS TECHNOLOGIES CORPORATION (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118032958-A | HPLC quantitative detection method of chondroitin sulfate based on GalN-AQC derivatization | 中国检验检疫科学研究院 | 2024-05-14 | — | — | CN | disclosed |
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3744708-B1 | CALIBRANT FOR LIQUID CHROMATOGRAPHY CALIBRATION OF LABELED N-GLYCANS | WATERS TECHNOLOGIES CORP (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3744708-B1 | CALIBRANT FOR LIQUID CHROMATOGRAPHY CALIBRATION OF LABELED N-GLYCANS | WATERS TECHNOLOGIES CORP (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220268779-A1 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | WATERS TECHNOLOGIES CORPORATION (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4033223-A1 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | Waters Technologies Corporation (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20160195564-A1 | AUTOMATED SAMPLING AND REACTION SYSTEM FOR HIGH PRESSURE LIQUID CHROMATOGRAPHY AND OTHER TYPES OF DETECTION | WATERS TECHNOLOGIES CORPORATION (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2016077548-A1 | METHODS FOR LIQUID CHROMATOGRAPHY CALIBRATION FOR RAPID LABELED N-GLYCANS | WATERS TECHNOLOGIES CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20130172528-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130102478-A1 | INTERNAL STANDARDS AND METHODS FOR USE IN QUANTITATIVELY MEASURING ANALYTES IN A SAMPLE | WATERS TECHNOLOGIES CORPORATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120184497-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. | 2012-07-19 | — | — | US | disclosed |
| US-8143212-B2 | Dalbavancin compositions for treatment of bacterial infections | VICURON PHARMACEUTICALS INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143212-B2 | Dalbavancin compositions for treatment of bacterial infections | VICURON PHARMACEUTICALS INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090298749-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298749-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | VICURON PHARMACEUTICALS INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009070233-A1 | INTERNAL STANDARDS AND METHODS FOR USE IN QUANTITATIVELY MEASURING ANALYTES IN A SAMPLE | WATERS TECHNOLOGIES CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172528-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | PWWP2B, TREH, CUTA | NPC1 3338/4885POLB 200/4885MEN1 2474/4885 |
| US-20120184497-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | DAD1, CFB, STT3B | NPC1 959/4885POLB 2692/4885MEN1 432/4885 |
| US-20090298749-A1 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS | CUTA, MAGT1, C1S | NPC1 1958/4885POLB 572/4885MEN1 469/4885 |
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | DDOST, STT3B, CSGALNACT1 | NPC1 2798/4885POLB 1377/4885MEN1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.